The MHRA has approved tisotumab vedotin for adults with recurrent or metastatic cervical cancer, offering a new option after ...
Adding a six-week course of chemotherapy to the standard course of treatment for locally advanced cervical cancer resulted in a significant increase in survival rates, a new study shows.The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback